Expression pattern of FOS in orexin neurons during sleep induced by an adenosine A2A receptor agonist.
The present study examined the expression pattern of FOS in the hypothalamic peptide neurons during the sleep-dominant state induced by an adenosine A2A receptor agonist. The control rats, those that received the microdialysis-perfusion of their ventral striatum with artificial cerebrospinal fluid in the dark-active phase, spent 24% of the 90-min period prior to sacrifice in non-rapid eye movement (non-REM) sleep and 2.3% of that in REM sleep. These rats exhibited FOS, a transcription factor, in 21% of their orexin neurons and in 1.0% of their melanin-concentrating hormone (MCH) neurons in the perifornical/lateral hypothalamic areas. However, the rats perfused with 50 microM CGS21680, an adenosine A2A receptor agonist, spent 60% of the 90-min period prior to sacrifice in non-REM sleep and 11% of that in REM sleep. These rats exhibited FOS in 1.7% of their orexin neurons and FOS in 0.5% of their MCH neurons. When the sleep-dominant state was disturbed by mild stimulation and the rats were kept in the sleepy state by treatment with a sleep-inducing dose of CGS21680, the rats exhibited FOS in 13.3% of their orexin neurons, which percentage was about half of that for the control rats. These results suggest that the sleep-promoting process induced by this adenosine A2A receptor agonist was associated with a decline in the activity of orexin neurons. MCH neurons are not likely to change their activities during this sleep-promoting process.
Satoh
Shinsuke
S
Department of Neuropsychiatry, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan. knssat@yahoo.co.jp
Matsumura
Hitoshi
H
Kanbayashi
Takashi
T
Yoshida
Yasushi
Y
Urakami
Takahito
T
Nakajima
Tomoko
T
Kimura
Nobuko
N
Nishino
Seiji
S
Yoneda
Hiroshi
H
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D058908:Adenosine A2 Receptor Agonists; D000818:Animals; D002452:Cell Count / Q000379:methods; D015870:Gene Expression / Q000187:drug effects; D007028:Hypothalamic Hormones / Q000378:metabolism; D007031:Hypothalamus / Q000166:cytology; D007150:Immunohistochemistry / Q000379:methods; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008297:Male; D008543:Melanins / Q000378:metabolism; D009474:Neurons / Q000187:drug effects*; D009479:Neuropeptides / Q000378:metabolism*; D016761:Oncogene Proteins v-fos / Q000378:metabolism*; D064446:Orexin Receptors; D000068797:Orexins; D010627:Phenethylamines / Q000494:pharmacology*; D010907:Pituitary Hormones / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D012890:Sleep / Q000187:drug effects*; D018709:Statistics, Nonparametric
D058908:Adenosine A2 Receptor Agonists; D007028:Hypothalamic Hormones; D047908:Intracellular Signaling Peptides and Proteins; D008543:Melanins; D009479:Neuropeptides; D016761:Oncogene Proteins v-fos; D064446:Orexin Receptors; D000068797:Orexins; D010627:Phenethylamines; D010907:Pituitary Hormones; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; C019463:melanin-concentrating hormone; D000241:Adenosine